Publicity on the Beta-Blocker Heart Attack Trial (Continued)

Publisher Website
Google Scholar
Abstract
To the Editor: The letter in the February 11 issue from Pickering,1 critical of the "publicity" on the Beta-Blocker Heart Attack Trial (BHAT), warrants correction and comment. The BHAT was designed to determine whether long-term administration of the beta-blocker propranolol to patients who had recently survived heart attacks would result in a significant reduction in mortality.Pickering states that the BHAT findings were released at a press conference, followed by "two brief and anecdotal reports" in Science and the Journal of the American Medical Association. 2 The article in JAMA was a preliminary report prepared by the BHAT Study Group. Although . . .

This publication has 2 references indexed in Scilit: